Nucala 100 MG/ML powder vials
Ended Awarded
- Contract number
- SPE2DB25FM8HN
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,859
Award facts
- Contract value 100% obligated
- $5,858.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $5,858.97 for NUCALA 100 mg/ml powder vials. This award, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The contract carries no set-aside designation, allowing the company to compete on its merits within the federal pharmaceutical supply market. NUCALA (mepolizumab) is a monoclonal antibody used to treat eosinophilic conditions and certain asthma types, reflecting DLA's role in supplying specialized pharmaceutical products to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's significant $499.999 billion single-award IDC with DLA through the SPE2DB program, valid through November 2026. The parent contract enables DLA to procure a comprehensive range of pharmaceutical items including branded and generic prescription drugs, biologics, and medical consumables to support military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier in the federal pharmaceutical supply chain, consistently leveraging its woman-owned small business status to secure federal contracts for diverse medical products ranging from specialty medications to vaccines and oncology treatments.
Quick answers
Who was awarded contract SPE2DB25FM8HN?
SPE2DB25FM8HN was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FM8HN worth?
The government has obligated $5,859 on SPE2DB25FM8HN.
Is contract SPE2DB25FM8HN an order under another contract?
Yes. SPE2DB25FM8HN is a delivery order under SPE2DB22D9151, an indefinite delivery contract.
Was contract SPE2DB25FM8HN competed?
The extent of competition for SPE2DB25FM8HN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award